$9.10
2.59% today
Nasdaq, Nov 26, 09:17 pm CET
ISIN
US2210151005
Symbol
CRVS

Corvus Pharmaceuticals, Inc. Stock price

$8.87
+1.01 12.85% 1M
+5.38 154.15% 6M
+3.52 65.79% YTD
-0.06 0.67% 1Y
+7.98 891.28% 3Y
+4.97 127.44% 5Y
-5.38 37.75% 10Y
-5.38 37.75% 20Y
Nasdaq, Closing price Tue, Nov 25 2025
+0.29 3.38%
ISIN
US2210151005
Symbol
CRVS
Industry

Key metrics

Basic
Market capitalization
$662.4m
Enterprise Value
$596.7m
Net debt
positive
Cash
$65.7m
Shares outstanding
74.7m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | 1,047.5
EV/Sales
- | 943.6
EV/FCF
negative
P/B
9.2
Financial Health
Equity Ratio
47.3%
Return on Equity
-191.3%
ROCE
-53.7%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $632.4k
EBITDA
$-38.8m | -
EBIT
$-38.9m | $-42.7m
Net Income
$-15.1m | $-20.5m
Free Cash Flow
$-32.2m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-55.0% | -
EBIT
-54.9% | -55.1%
Net Income
73.5% | 67.2%
Free Cash Flow
-45.7%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -3,235.0%
Free Cash Flow
-
More
EPS
$-0.2
FCF per Share
$-0.4
Short interest
15.3%
Employees
31
Rev per Employee
$0.0
Show more

Is Corvus Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,053 stocks worldwide.

Corvus Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a Corvus Pharmaceuticals, Inc. forecast:

12x Buy
92%
1x Hold
8%

Analyst Opinions

13 Analysts have issued a Corvus Pharmaceuticals, Inc. forecast:

Buy
92%
Hold
8%

Financial data from Corvus Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 9.11 9.11
19% 19%
-
- Research and Development Expense 30 30
71% 71%
-
-39 -39
55% 55%
-
- Depreciation and Amortization 0.10 0.10
0% 0%
-
EBIT (Operating Income) EBIT -39 -39
55% 55%
-
Net Profit -15 -15
73% 73%
-

In millions USD.

Don't miss a Thing! We will send you all news about Corvus Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Corvus Pharmaceuticals, Inc. Stock News

Neutral
Seeking Alpha
22 days ago
Corvus Pharmaceuticals, Inc. ( CRVS ) Q3 2025 Earnings Call November 4, 2025 4:30 PM EST Company Participants Leiv Lea - Chief Financial Officer Richard Miller - Co-Founder, President, CEO & Chairman of the Board Conference Call Participants Zack Kubow - Real Chemistry, Inc. Graig Suvannavejh - Mizuho Securities USA LLC, Research Division Jeffrey Jones - Oppenheimer & Co. Inc., Research Divisio...
Neutral
GlobeNewsWire
22 days ago
Completed enrollment in soquelitinib atopic dermatitis Phase 1 trial extension cohort 4 (200 mg BID dose with 8-week treatment period) with data announcement anticipated in January Soquelitinib atopic dermatitis phase 2 trial on track to initiate in early Q1 2026 Phase 3 registrational clinical trial of soquelitinib in relapsed/refractory peripheral T cell lymphoma (PTCL) enrolling with multipl...
Neutral
GlobeNewsWire
26 days ago
SOUTH SAN FRANCISCO, Calif., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will conduct one-on-one meetings with investors and participate in a fireside chat presentation at the Guggenheim 2nd Annual Healthcare Innovation Conference, which is being held in Boston, MA....
More Corvus Pharmaceuticals, Inc. News

Company Profile

Corvus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of oncology therapies. The company focuses on disabling cancer's ability to subvert immune attack by inhibiting adenosine in the tumor microenvironment and by blocking its production by tumors. Its product pipeline includes Adenosine A2A Receptor Antagonist CPI-444, Adenosine Production Inhibitor Anti-CD73, Adenosine A2B Receptor Antagonist, ITK Inhibitor, and Myeloid Cell Suppression. The company was founded by Richard A. Miller, Peter A. Thompson, and Joseph J. Buggy on January 27, 2014 and is headquartered in Burlingame, CA.

Head office United States
CEO Richard Miller
Employees 31
Founded 2014
Website www.corvuspharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today